A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates. The results from the clinical trial of ENZAMET, co-chaired by Professor Christopher Sweeney, have been published. For people with metastatic hormone-sensitive prostate cancer, the addition of an androgen receptor blocker with enzalutamide to standard therapy—suppression of testosterone, with or without chemotherapy—led to a 67 percent survival rate after five years. This compares to 57 percent of people who were alive after five years after receiving the standard best practice treatment. "The longer-term analysis showed that the benefit of adding enzalutamide was evident in...